Skip to main content
Atrás
Watch Compare

REGENEREX PHARMA, INC.

Calidad de datos: 67%
RGPX
OTC Manufacturing Chemicals

Quick Summary

Puntos Clave

Negative free cash flow of -1.33 M

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio0.01
Interest Coverage-33.24

Valoración

P/E Ratio
N/A
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (44 pares)
Métrica Acción Mediana del Sector
P/E — -2.0
P/B — 5.1
ROE % — -51.0
Net Margin % — -150.2
Rev Growth 5Y % — 9.3
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -4.49 M
ROE N/A ROA -710.39%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -1.33 M
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.01
Interest Coverage -33.24 Asset Turnover N/A
Working Capital -4.88 M Tangible Book Value -4.70 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio N/A Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield N/A
Market Cap N/A Enterprise Value N/A
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share N/A OCF / Share N/A
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 29.57%
SBC-Adj. FCF -1.84 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2019
Revenue — — — 2,608.0 2,608.0
Net Income -3.54 M -137,330.0 -195,591.0 111,589.0 -93,579.0
EPS (Diluted) — — — — —
Gross Profit — — — 896.0 896.0
Operating Income -3.47 M -96,171.0 -126,267.0 -77,003.0 -91,734.0
EBITDA — — — — —
R&D Expenses 2.40 M 2.40 M — — —
SG&A Expenses 1.07 M — — — —
D&A — — — — —
Interest Expense 80,638.0 66,788.0 59,063.0 28,658.0 778.0
Income Tax -2,717.0 — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2020 FY2019
Total Assets 766,680.0 6,539.0 15,322.0 259,167.0 105,623.0
Total Liabilities 4.83 M 1.13 M 1.00 M 740,441.0 475,308.0
Shareholders' Equity -4.06 M -1.12 M -985,617.0 -481,274.0 -369,685.0
Total Debt 184,232.0 184,232.0 — — —
Cash & Equivalents 372.0 1,135.0 2,640.0 5,460.0 88,546.0
Current Assets 2,912.0 1,135.0 7,896.0 252,151.0 97,616.0
Current Liabilities 3.84 M 776,782.0 660,453.0 518,718.0 405,308.0